Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

ANI Pharmaceuticals (BSFA) Price & Analysis

BSFA Stock Chart & Stats

€64.50-€1.00(-1.53%)
At close: 4:00 PM EDT
EUR 64EUR 64.5EUR 65EUR 65.517 Aug30 Sep15 Oct
Day’s Range
EUR 64.00 - EUR 65.50
52-Week Range
EUR 59.50 - EUR 81.00
Previous Close
EUR 65.50
Volume
0
Average Volume (3M)
4
Market Cap
EUR 1.48B
Enterprise Value
EUR 2.05B
Total Cash (Recent Filing)
EUR 360.21M
Total Debt (Recent Filing)
EUR 330.34M
Price to Earnings (P/E)
14.9
Beta
0.23
Next Earnings
Nov 05, 2026
EPS Estimate
1.95
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Cortrophin Growth

Cortrophin is becoming a major growth platform, with expanding demand across multiple specialties and a larger commercial team. Sustained adoption could materially improve ANI’s revenue mix and support continued operating leverage.

Generics Pipeline

Consistent generic launches and in-house pharmaceutical capabilities provide recurring opportunities to replace mature products and broaden revenue. This pipeline also diversifies growth beyond Cortrophin and supports manufacturing scale.

Balance Sheet

Strong operating cash generation, substantial liquidity and reduced net leverage improve ANI’s financial flexibility. The healthier capital structure can support product investment, business development and execution through operating volatility.

Bears Say

Cortrophin Timing Risk

Although Cortrophin remains a strong growth driver, the guidance adjustment shows that demand conversion and timing are not fully predictable. Continued execution or access friction could make results more dependent on one product.

Margin Pressure

Higher manufacturing costs and investment in the expanded gout sales force are absorbing part of the revenue benefit. If these expenses persist faster than product growth, margin expansion and earnings conversion could remain constrained.

Earnings Consistency

The historical losses and weaker recent cash-flow growth indicate that profitability is not yet consistently resilient. Working-capital effects, one-time items or cost swings could reduce the reliability of reported earnings and cash generation.

ANI Pharmaceuticals News

BSFA FAQ

What was ANI Pharmaceuticals’s price range in the past 12 months?
ANI Pharmaceuticals lowest stock price was €59.50 and its highest was €81.00 in the past 12 months.
What is ANI Pharmaceuticals’s market cap?
ANI Pharmaceuticals’s market cap is €1.48B.
When is ANI Pharmaceuticals’s upcoming earnings report date?
ANI Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were ANI Pharmaceuticals’s earnings last quarter?
ANI Pharmaceuticals released its earnings results on Aug 07, 2026. The company reported €1.972 earnings per share for the quarter, beating the consensus estimate of €1.823 by €0.149.
Is ANI Pharmaceuticals overvalued?
According to Wall Street analysts ANI Pharmaceuticals’s price is currently Undervalued.
Does ANI Pharmaceuticals pay dividends?
ANI Pharmaceuticals does not currently pay dividends.
What is ANI Pharmaceuticals’s EPS estimate?
ANI Pharmaceuticals’s EPS estimate is 1.95.
How many shares outstanding does ANI Pharmaceuticals have?
ANI Pharmaceuticals has 22,959,488 shares outstanding.
What happened to ANI Pharmaceuticals’s price movement after its last earnings report?
ANI Pharmaceuticals reported an EPS of €1.972 in its last earnings report, beating expectations of €1.823. Following the earnings report the stock price went up 0.704%.
Which hedge fund is a major shareholder of ANI Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:BSFA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology